PRL action on E2 ovarian secretion.
5 Amenorrhea hyperprolactinemic women in previous intermittent treatment with bromocryptine, received bromocryptine for three periods of 5, 4, 3 days; each treatment phase was followed by a ten days suspension. During treatment and during suspension FSH, LH, PRL and E2 were tested. There was no significative variation of FSH and LH; PRL lowered during treatment and reached basal values during suspension. Ovarian response (E2) varies with PRL levels. There was a statistically significative negative correlation between PRL and 17-beta-E2.
D000328:Adult; D000568:Amenorrhea / Q000097:blood* / Q000188:drug therapy; D001971:Bromocriptine / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010053:Ovary / Q000378:metabolism*; D011388:Prolactin / Q000097:blood*
D001971:Bromocriptine; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone